Q-omics provides the consensus-scored ANP32C profile across patient tissues and cancer cell-line models. ANP32C expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ANP32C is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, ANP32C RNA expression shows 13,657 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, COAD, and GBM as cancer lineages where ANP32C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANP32C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANP32C survival associations across molecular data types. ANP32C RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANP32C RNA expression–survival associations across cancer types. High ANP32C expression shows unfavorable associations in MESO, ACC and KIRP, but favorable associations in CESC, THCA and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for ANP32C RNA expression.
This table summarizes ANP32C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ANP32C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANP32C shows lower tumor expression in KIRP and higher tumor expression in COAD, READ, LUSC, HNSC and STAD. The COAD box plot shows higher ANP32C RNA expression in tumor versus normal tissue (log2 FC = +0.408, t-test p < 0.001).
This table shows molecular features associated with ANP32C in patient tissues and cancer cell lines. In patient samples, ANP32C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANP32C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and NCI60_ALL.
